361 Capital LLC bought a new position in shares of Lantheus Holdings Inc (NASDAQ:LNTH) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 108,594 shares of the medical equipment provider’s stock, valued at approximately $1,933,000. 361 Capital LLC owned about 0.29% of Lantheus at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Cypress Capital Management LLC WY bought a new stake in Lantheus during the third quarter worth $382,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of Lantheus in the 3rd quarter valued at $517,000. Russell Investments Group Ltd. lifted its stake in shares of Lantheus by 14.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 321,681 shares of the medical equipment provider’s stock valued at $5,726,000 after acquiring an additional 41,028 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Lantheus by 18.3% in the 3rd quarter. Bank of New York Mellon Corp now owns 432,973 shares of the medical equipment provider’s stock valued at $7,708,000 after acquiring an additional 66,925 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of Lantheus by 5.0% in the 3rd quarter. Rhumbline Advisers now owns 53,702 shares of the medical equipment provider’s stock valued at $956,000 after acquiring an additional 2,560 shares during the last quarter. Hedge funds and other institutional investors own 91.95% of the company’s stock.
A number of research analysts have recently commented on LNTH shares. Jefferies Group increased their price target on Lantheus from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Friday, November 3rd. Wells Fargo & Company upgraded Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday, November 2nd. Zacks Investment Research upgraded Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 price target for the company in a report on Tuesday, November 7th. Credit Suisse Group increased their price objective on shares of Lantheus from $19.00 to $23.00 and gave the stock a “neutral” rating in a research report on Friday, November 3rd. Finally, ValuEngine cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $24.50.
Lantheus Holdings Inc (LNTH) traded down $1.10 during trading on Monday, hitting $20.75. 419,307 shares of the company’s stock traded hands, compared to its average volume of 552,412. Lantheus Holdings Inc has a 1 year low of $7.95 and a 1 year high of $24.10. The company has a debt-to-equity ratio of -3.41, a quick ratio of 2.46 and a current ratio of 2.96. The company has a market cap of $819.51, a PE ratio of 19.51, a P/E/G ratio of 1.73 and a beta of 0.94.
Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.04. Lantheus had a net margin of 9.59% and a negative return on equity of 46.45%. The firm had revenue of $79.94 million for the quarter, compared to analysts’ expectations of $77.18 million. During the same quarter last year, the firm earned $0.15 EPS. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. sell-side analysts expect that Lantheus Holdings Inc will post 1.05 EPS for the current fiscal year.
In related news, insider Cesare Orlandi sold 18,000 shares of Lantheus stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $16.69, for a total value of $300,420.00. Following the completion of the transaction, the insider now directly owns 87,078 shares in the company, valued at approximately $1,453,331.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David F. Burgstahler sold 52,010 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $17.08, for a total transaction of $888,330.80. Following the transaction, the director now owns 13,248 shares of the company’s stock, valued at $226,275.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 316,787 shares of company stock valued at $5,446,943. 2.30% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/04/361-capital-llc-buys-shares-of-108594-lantheus-holdings-inc-lnth.html.
Lantheus Company Profile
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.